Everything below concerns Semax. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
=== Differences from deepfakes === Although AI-generated pornography and deepfake pornography rely on similar generative AI technologies, deepfakes involve altering existing content, usually photographs of unconsenting individuals, while AI-generated pornography usually synthesizes explicit content from scratch without using people's likenesses directly. Digital image analysis expert Hany Farid opined that, while deepfake pornography of unconsenting individuals should be illegal, the legal status of AI-generated pornography created from scratch is "more complex".
==== Sirenia research ==== Saha, Bhardwaj & Bajpai (2026) study the restructuring of the sirenian skull throughout the evolutionary history of the group on the basis of data from extant and fossil taxa. Wagner et al. (2026) provide a methodology for quantification of the degree of pachyostosis in ribs and vertebrae of sirenians on the basis of the study of extant and extinct taxa. Pérez-Ramos et al. (2026) present a virtual reconstruction of the vertebral column of Pezosiren portelli. New fossil material of sirenians with dugongid affinities, associated with an invertebrate assemblage that might be indicative of presence of seagrass habitats, is described from the Oligocene strata of the Maniyara Fort Formation (India) by Joshi et al. (2026). Shinmura & Sawada (2026) reconstruct diets of sirenians from Miocene to Pliocene marine sediments in Hokkaido (Japan) on the basis of stable carbon isotope ratios of fatty acids and sterols extracted from their bones, providing evidence of Metaxytherium feeding on seagrass and evidence of feeding of Dusisiren and the Takikawa sea cow on seaweed.
=== Complications === Complications may include urinary retention, recurring urinary tract infections and incontinence. The anterior vaginal wall may protrude though the vaginal introitus (opening). This can interfere with sexual activity. Recurrent urinary tract infections are common for those who have urinary retention. In addition, though cystocele can be treated, some treatments may not alleviate troubling symptoms, and further treatment may need to be performed. Cystoceles may affect the quality of life; women who have cystoceles tend to avoid leaving their homes and avoid social situations. The resulting incontinence puts women at risk of being placed in a nursing home or long-term care facility.
for molecular models that are more realistic than rigid elastic spheres, such as those incorporating intermolecular attractions. Doing so is necessary to reproduce the correct temperature dependence of
== Publishers == George Haven Putnam* (1864), publisher of G. P. Putnam's Sons, son of publisher George Palmer Putnam Henry S. Harper (1888), director of Harper and Brothers, Titanic survivor Bernard H. Ridder (1903), publisher of The St. Paul Dispatch and The Pioneer Press, chairman emeritus of Ridder Publications Alfred Harcourt (1904) and Donald Brace (1904), founders of Harcourt Brace Joseph E. Ridder (1907), publisher of The Journal of Commerce and chairman of Ridder Publications John Neville Wheeler (1908), founder and owner of the North American Newspaper Alliance and Bell Syndicate Harold Latham (1909), editor-in-chief of Macmillan Inc., known for discovering Margaret Mitchell Alfred A. Knopf (1912), founder and chairman of Alfred A. Knopf George T. Delacorte Jr. (1913), founder of Dell Publishing Arthur Hays Sulzberger (1913), publisher of The New York Times Douglas Black (1916), president of Doubleday and Company Bennett Cerf (1920), founder of Random House Donald S. Klopfer* (1922), founder of Random House Richard L. Simon (1920) and Max Lincoln Schuster (1919), co-founders of Simon & Schuster Elliott V. Bell (1925), former editor and publisher of Businessweek David A. Boehm (1934), founder of Sterling Publishing Robert Giroux (1936), chairman of Farrar, Straus and Giroux Ian Ballantine (1938), founder of Ballantine Books Walter B. Pitkin Jr. (1938), editor-in-chief and executive vice president of Bantam Books William D.
Sources: en.wikipedia.org
== Awards == 2018, Discovery in Proteomic Sciences Award from the Human Proteome Organization (HUPO). 2012, Biemann Medal, for work on electron-transfer dissociation (ETD) 2010, Pittsburgh Conference Achievement Award 2009, Ken Standing Award, University of Manitoba 2008, National Science Foundation CAREER Award 2007, American Society of Mass Spectrometry Research Award for “significant achievement in basic or applied mass spectrometry made by an individual early in his or her career” 2007, Beckman Young Investigators Award 2007, Eli Lilly and Company Young Investigator Award 2006, One of "Tomorrow's PIs" chosen by Genome Technology magazine
== Pharmacokinetics == When comparing the pharmacokinetic properties of spironolactone and eplerenone, it is clear that the two drugs differ. Spironolactone has shorter half-life (t1/2 = 1.3-1.4 hours) than eplerenone (t1/2 = 4–6 hours). Eplerenone goes through rapid metabolism by the liver to inactive metabolites (t1/2 = 4–6 hours). However, spironolactone is metabolized to three active metabolites, which give it prolonged activity (13.8 – 16. 5 hours). Spironolactone has a long half-life and is excreted 47-51% through kidneys. Patients with chronic kidney disease therefore require close monitoring when taking the drug. Spironolactone is also eliminated through feces (35-41%). The excretion of eplerenone is 67% through kidneys and 32% through feces. The information about excretion plays a critical role when determining the appropriate doses for patients with renal and/or hepatic dysfunction. It is very important to adjust the doses for patients with renal dysfunction because if they fail to eliminate the drug through their kidneys it could accumulate in the body, causing high concentration of potassium in the blood.
The last eukaryotic common ancestor (LECA) is the hypothetical most recent common ancestor of all living eukaryotes – organisms whose cells have a nucleus, around 2 billion years ago. The process by which the LECA came into being, eukaryogenesis, is not understood in detail, but is thought to have involved symbiogenesis, the coming together of an archaean and a bacterium which formed the cell's mitochondria. The LECA's structure and function have been reconstructed by comparing the genomes of modern eukaryotes. This has led biologists to propose that the LECA was a complex cell with a nucleus with a nucleolus and eu/heterochromatin, an endoplasmic reticulum, peroxisomes, endo- and lysosomes, the ESCRT system, a Golgi apparatus, actin-based endo- and exocytosis, pseudopodia or filopodia, sterol-based membranes, G3P + ester bond phospholipids, a microtubule-based cytoskeleton with an organising centre, basal bodies, vacuoles, iron-sulphur cluster biosynthesis via the CIA system, mitochondria, and microtubule-based flagella.
Microfluidic liquid-liquid extraction has shown to be advantageous in numerous applications such as pharmacokinetic drug studies where only small cell numbers are needed, and in additional studies where smaller reagent volumes are required. Droplet-based microfluidics can also be used for chemical phase transfer reactions. An early example was the synthesis of azo dyes in nanoliter fluid segments using a double injector chip device.
α1C, α1D, and α2/δ1 subunits showed an increase of expression after sustained ethanol exposure. However, the β4 subunit showed a decrease. Furthermore, α1A, α1B, and α1F subunits did not alter in their relative expression. Thus, sustained ethanol exposure may participate in the development of ethanol dependence in neurons. Other experiments done by Malysz et al. have looked into ethanol effects on voltage-gated calcium channels on detrusor smooth muscle cells in guinea pigs. Perforated patch clamp technique was used having intracellular fluid inside the pipette and extracellular fluid in the bath with added 0.3% vol/vol (about 50-mM) ethanol. Ethanol decreased the Ca2+ current in DSM cells and induced muscle relaxation. Ethanol inhibits VGCCs and is involved in alcohol-induced relaxation of the urinary bladder.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.